UPDATE: Correction - Nomura Securities Maintains a 'Buy' on NVIDIA (NVDA); ASUS Announcement Highlights Progress
Get Alerts NVDA Hot Sheet
Price: $225.16 -0.06%
Rating Summary:
58 Buy, 10 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
58 Buy, 10 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - July 18, 2012 9:56 AM EDT)
Correction - Nomura Securities maintains a 'Buy' on NVIDIA (NASDAQ: NVDA) price target of $18.00.
Analyst, Romit Shah said, "ASUS announced that it will use NVIDIA’s Icera modem along with the Tegra 3 processor in its upcoming Win RT tablet. This announcement highlights progress toward commercializing the Icera LTE modem. While positive, we do not see these design wins affecting estimates meaningfully. We estimate design wins at ASUS and ZTE would generate $50-70mn in incremental revenue and $0.02-$0.03 in EPS in CY12. We are positive on shares of NVIDIA, which trade at near historically low multiples of 13x earnings and 1x EV/sales."
For an analyst ratings summary and ratings history on NVIDIA click here. For more ratings news on NVIDIA click here.
Shares of NVIDIA closed at $12.37 yesterday.
Correction - Nomura Securities maintains a 'Buy' on NVIDIA (NASDAQ: NVDA) price target of $18.00.
Analyst, Romit Shah said, "ASUS announced that it will use NVIDIA’s Icera modem along with the Tegra 3 processor in its upcoming Win RT tablet. This announcement highlights progress toward commercializing the Icera LTE modem. While positive, we do not see these design wins affecting estimates meaningfully. We estimate design wins at ASUS and ZTE would generate $50-70mn in incremental revenue and $0.02-$0.03 in EPS in CY12. We are positive on shares of NVIDIA, which trade at near historically low multiples of 13x earnings and 1x EV/sales."
For an analyst ratings summary and ratings history on NVIDIA click here. For more ratings news on NVIDIA click here.
Shares of NVIDIA closed at $12.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Needham & Company, Nomura, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share